Urgent

HIV / hepatitis B / hepatitis C post-exposure prophylaxis

PEP · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

After occupational (needlestick) or non-occupational (sexual, injecting) exposure to blood/body fluids, rapid risk assessment guides HIV post-exposure prophylaxis and hepatitis B/C management. HIV PEP is time-critical and most effective started within hours, and useless beyond 72 hours.

Red flags

  • Presentation beyond 72 h for HIV exposure (PEP no longer effective)
  • Deep injury with hollow-bore blood-filled needle from viraemic source
  • Known resistant source HIV virus (seek specialist regimen)
  • Established acute HIV symptoms
  • Pregnancy requiring tailored regimen

Assessment

Differential diagnosis

  • Negligible-risk exposure not needing PEP
  • Source known HIV positive and suppressed (lower risk)
  • High-risk mucosal/percutaneous HIV exposure
  • Hepatitis B exposure in non-immune person
  • Hepatitis C exposure (no prophylaxis, monitor)

Investigations

  • Baseline HIV antigen/antibody of exposed person
  • Hepatitis B surface antibody/antigen and core status
  • Hepatitis C antibody (and source where consentable)
  • Renal and liver function before PEP
  • Pregnancy test
  • Source testing where possible (HIV, HBsAg, HCV)

Management

  • Perform first aid: wash wound, irrigate mucosa; do not squeeze/suck
  • Risk-assess exposure type, fluid and source status urgently
  • If HIV risk significant, start PEP immediately (within 72 h, ideally hours)
  • Send baseline bloods; obtain source-patient testing with consent
  • For hepatitis B: give accelerated vaccine +/- immunoglobulin based on immunity and source
  • No prophylaxis for hepatitis C; arrange monitoring and early treatment if seroconversion
  • Counsel on adherence, side effects, and safe sex/no donation during follow-up
  • Provide emergency contraception and STI screening after sexual exposure
  • Review at 48-72 h to confirm indication and tolerability
  • Continue HIV PEP for 28 days
  • Repeat HIV test at 6-8 weeks (and 12 weeks if indicated); hepatitis C RNA/antibody follow-up
  • Refer occupational exposures to occupational health

Drugs & doses

Tenofovir disoproxil/emtricitabine 245/200 mg PO once daily plus raltegravir 400 mg PO twice daily (or dolutegravir 50 mg once daily) for 28 days
Hepatitis B immunoglobulin 500 units IM (within 48 h) if non-immune and source infectious
Hepatitis B vaccine accelerated schedule 0, 1, 2 months (plus 12 months)
Emergency contraception (levonorgestrel 1.5 mg PO) after sexual exposure as needed

Disposition

Emergency department / occupational health / sexual health; urgent start then specialist follow-up.

Complications & pitfalls

  • HIV seroconversion despite PEP (adherence/resistance)
  • PEP gastrointestinal/renal side effects and non-completion
  • Hepatitis B acquisition in unprotected person
  • Hepatitis C chronic infection
  • Anxiety and loss to follow-up

Exam pearls

  • Start PEP first, refine regimen later once source status known
  • If source is HIV positive with confirmed undetectable load, PEP often not required
  • Hepatitis C has no prophylaxis but highly curable if detected early
  • Document all occupational exposures and report per local policy
  • Confirm hepatitis B immunity with anti-HBs level where possible

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.